**Question:** Antibodies against phospholipase A2 receptors are seen in

A. Systemic Lupus Erythematosus (SLE)
B. Rheumatoid Arthritis (RA)
C. Chronic Hepatitis C Virus (HCV) infection
D. Multiple Sclerosis (MS)

**Core Concept:** Phospholipase A2 receptors (PLA2R) are proteins found on the surface of the glomerular cells in the kidneys. They play a role in maintaining the structure and function of the glomerulus. Antibodies against PLA2R are a hallmark of a specific autoimmune disease, which targets these receptors and leads to kidney damage.

**Why the Correct Answer is Right:** Antibodies against phospholipase A2 receptors are found in patients with Minimal Change Disease (MCD), a subtype of primary glomerulonephritis. In this case, the immune system mistakenly attacks the PLA2R, causing inflammation and damage to the glomerulus. Among the given options, the correct answer is C: Chronic Hepatitis C Virus (HCV) infection. Chronic HCV infection can lead to the development of HCV-associated membranous nephropathy, which is a form of glomerulonephritis, and antibodies against PLA2R are detected in these patients.

**Why Each Wrong Option is Incorrect:**

A. Systemic Lupus Erythematosus (SLE) is an autoimmune disease affecting multiple organs, not specifically targeting PLA2R in the kidney. Antibodies against SLE are directed against nuclear antigens rather than renal antigens.

B. Rheumatoid Arthritis (RA) is an autoimmune disease affecting joints, not specifically targeting PLA2R in the kidney. Antibodies against RA are directed against citrullinated proteins, not renal antigens.

D. Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system, not targeting PLA2R in the kidney. Antibodies against MS are directed against myelin, not renal antigens.

**Clinical Pearl:** Antibodies against PLA2R are a useful diagnostic tool in identifying patients with membranous nephropathy, especially when combined with other diagnostic markers and clinical findings. It helps in distinguishing it from other renal diseases, such as minimal change disease, and guides appropriate management strategies.